CoChat

Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial

Open access

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To evaluate the impact of once-weekly exenatide (EQW) on microvascular and cardiovascular (CV) outcomes by baseline renal function in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). RESEARCH DESIGN AND METHODS: Least squares mean difference (LSMD) in estimated glomerular filtration rate (eGFR) from baseline between the EQW and placebo groups was calculated for 13,844 participants. Cox regression models were used to estimate effects by group on incident macroalbuminuria, retinopathy, and major adverse CV events (MACE). Interval-censored time-to-event models estimated effects on renal composite 1 (40% eGFR decline, renal replacement, or renal death) and renal composite 2 (composite 1 variables plus macroalbuminuria). RESULTS: EQW did not change eGFR significantly (LSMD 0.21 mL/min/1.73 m2 [95% CI −0.27 to 0.70]). Macroalbuminuria occurred in 2.2% of patients in the EQW group and in 2.5% of those in the placebo group (hazard ratio [HR] 0.87 [95% CI 0.70–1.07]). Neither renal composite was reduced with EQW in unadjusted analyses, but renal composite 2 was reduced after adjustment (HR 0.85 [95% CI 0.74–0.98]). Retinopathy rates did not differ by treatment group or in the HbA1c-lowering or prior retinopathy subgroups. CV outcomes in those with eGFR <60 mL/min/1.73 m2 did not differ by group. Those with eGFR ≥60 mL/min/1.73 m2 had nominal risk reductions for MACE, all-cause mortality, and CV death, but interactions by renal function group were significant for only stroke (HR 0.74 [95% CI 0.58–0.93]; P for interaction = 0.035) and CV death (HR 1.08 [95% CI 0.85–1.38]; P for interaction = 0.031). CONCLUSIONS: EQW had no impact on unadjusted retinopathy or renal outcomes. CV risk was modestly reduced only in those with eGFR ≥60 mL/min/1.73 m2 in analyses unadjusted for multiplicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc19-1065

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

Items 101–117 of 117

Metadata

Authors
Bethel, M. A., Mentz, R. J., Merrill, P., Buse, J. B., Chan, J. C., Goodman, S. G., Iqbal, N., Jakuboniene, N., Katona, B., Lokhnygina, Y., Lopes, R. D., Maggioni, A. P., Ohman, P., Tankova, T., Bakris, G. L., Hernandez, A. F., & Holman, R. R.
Affiliations
  • Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
  • Duke University (US)
  • University of North Carolina at Chapel Hill (US)
  • Chinese University of Hong Kong (HK)
  • St. Michael's Hospital (CA)
  • AstraZeneca (United States) (US)
  • Department of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania
  • Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC
  • Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
  • AstraZeneca Research and Development, Gaithersburg, MD
  • Medical University of Sofia (BG)
  • University of Chicago (US)
Corresponding author
Holman, Rury R.
Venue
Diabetes Care
Published
2019-11-22
Volume
43
Issue
2
Pages
446-452
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2989595227
Cited by
112
References
32
Citations by year
2026: 7 · 2025: 22 · 2024: 9 · 2023: 22 · 2022: 22 · 2021: 13 · 2020: 17
FWCI
10.55
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Lithuanian University of Health Sciences (submittedVersion)
Funders
  • National Institute for Health and Care Research (NF-SI-0515-10096)
  • National Institutes of Health (UL1TR002489)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
exenatide, GLP-1 receptor agonists, renal function, estimated glomerular filtration rate, macroalbuminuria, diabetic retinopathy, major adverse cardiovascular events, cardiovascular risk reduction, renal function decline, stroke, renal replacement therapy, renal death, type 2 diabetes, EXSCEL trial, subgroup analysis, drug safety in renal impairment, all-cause mortality
MeSH terms
Exenatide, Aged, Cardiovascular Diseases, Cardiovascular System, Cause of Death, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Glomerular Filtration Rate, Humans, Kidney, Male, Middle Aged, Risk Factors, Survival Analysis, Treatment Outcome, Microvessels

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.